CASE REPORT

An N-terminal WT1 mutation (P181S) in an XY patient with ambiguous genitalia, normal testosterone production, absence of kidney disease and associated heart defect: enlarging the phenotypic spectrum of WT1 defects

Birgit Köhler, Catherine Pienkowski, Françoise Audran, Martine Delsol, Maïte Tauber, Françoise Paris, Charles Sultan and Serge Lumbroso

1Service d’Hormonologie and Institut National de la Santé et de la Recherche Médicale U540, CHU Montpellier, 2Service d’Endocrinologie Pédiatrique, 3Service d’Anatomie Pathologique, CHU Toulouse and 4Unité d’Endocrinologie Pédiatrique, CHU Montpellier, France

(Correspondence should be addressed to S Lumbroso; Email: lumbroso@montp.inserm.fr)

Abstract

Objective: This study reports the clinical and molecular data of an XY patient with a very unusual phenotype due to a Wilms’ tumor-suppressor (WT1) gene mutation. The genotype-phenotype relationship of different WT1 mutations is then discussed.

Patient: The patient presented at birth with micropenis, severe hypospadias and cryptorchidism. Normal androgen production and an absence of clinical response to a testosterone treatment trial suggested partial androgen resistance. Eventually, female sex of rearing was chosen. At the beginning of puberty, normal male androgen production occurred, and subsequent gonadectomy did not show gonadal dysgenesis. It is notable that the patient, now 20 years of age, has not developed kidney disease. In addition to the genital malformation, the patient displayed an associated congenital heart defect, consisting of a coarctation of the aorta and a patent ductus arteriosis (PDA).

Results: No mutations were detected in the androgen receptor or 5α-reductase genes. Direct sequencing of the WT1 gene identified a heterozygous proline to serine substitution at position 181 (P181S). The same heterozygous mutation was found in the mother. Interestingly, the mother shows no signs of kidney disease at her present age of 49.

Conclusion: This is the first germline missense mutation in the N-terminal part of WT1 identified in a patient with the very particular phenotype of ambiguous genitalia with absence of gonadal dysgenesis and kidney disease. The possible molecular mechanisms leading to the patient’s phenotype are considered. The high frequency of PDA in newborns and the absence of heart abnormalities in XX females carrying the P181S mutation, however, suggest that the heart defect was most likely a coincidental association. This case enlarges the clinical spectrum of WT1 defects and may provide new insights into the complex functions of WT1 in genital and kidney development.

European Journal of Endocrinology 150 825–830

Introduction

The Wilms’ tumor-suppressor (WT1) gene encodes a transcription factor of the zinc finger family which is known to play a major role in the development of the kidney and gonad. The gene was cloned in 1990 through patients with WAGR syndrome (Wilms’ tumor, aniridia, genitourinary malformation and mental retardation) who presented deletions of chromosome 11p13 (1). The WT1 gene consists of 10 exons and spans 50 kb. It may encode 24 protein isoforms through a combination of alternative splicing, alternative translational start sites and RNA editing. All these proteins share four C-terminal zinc fingers which are necessary for DNA/RNA-binding. The N-terminal part of WT1 is also of special functional importance, as it contains the self-association, repression and activation domains of the protein, as well as an RNA recognition motif (2). The two major isoforms are produced through alternative splicing at the end of exon 9, resulting in an insertion (+KTS) or exclusion (−KTS) of lysine, threonine and serine residues between zinc fingers 3 and 4. The +KTS and −KTS isoforms may perform distinct functions, as they are conserved during evolution. The +KTS isoform mainly plays a role in RNA processing and the −KTS isoform in transcriptional activity (3). Several lines of evidence have shown that WT1 can act as either a transcriptional activator or a repressor, both in vitro and in vivo (2, 4).

Since the cloning of WT1 in WAGR syndrome, numerous WT1 mutations have been described in two other syndromes associated with kidney disease.
and genital malformation. In the complete Denys–
Drash syndrome (DDS), WT1 missense mutations in
the zinc finger-coding region cause genital malfor-
mations in XY individuals, early-onset renal failure
due to diffuse mesangial sclerosis and Wilms’ tumor
(5). In Frasier syndrome, intron 9 splice-site mutations
affecting the balance of the + KTS/− KTS isoforms
were found to result in partial to complete male to
female sex reversal, late-onset renal failure due to
focal glomerulosclerosis, and gonadoblastoma (6). In
addition to these two-well defined disorders, WT1 non-
sense mutations were found in several patients with
genital abnormalities with or without Wilms’ tumor
(7, 8) and nephropathy (7, 9, 10). These observations
suggested that mutations of the WT1 gene are not
the cause of a defined syndrome, but rather lead to a
broad spectrum of disorders of the kidney and male
sex differentiation (11).

In this report we present the first N-terminal WT1
missense mutation (P181S) identified in an XY adult
patient with a very unusual phenotype: ambiguous geni-
talia but normal testosterone production, absence of
kidney disease and an associated congenital heart defect.

**Hormonal studies**

At birth, a testosterone (T) level of 0.31 ng/ml was
found. Basal luteinizing hormone (LH), follicle-stimu-
lating hormone (FSH) and 17 hydroxyprogesterone
after adrenocorticotropic hormone (ACTH) stimulation
were normal. Human chorionic gonadotropin (HCG)
stimulation (3 × 1500 IU) led to a normal testosterone
rise from 0.4 to 4.92 ng/ml (Table 1). A testosterone
treatment trial did not show growth of the peno-clitori-
dal structure. Consequently, the diagnosis of partial
androgen resistance was suggested.

**Case report**

**Clinical presentation**

The patient was born with ambiguous genitalia and
congenital heart disease. During pregnancy, the
mother did not receive any medication. Birth weight
was 2480 g and birth length was 46 cm at 37 weeks
of gestation. The genital malformation consisted of a
2.5 cm clitoris-like phallus, no palpable gonads, fusion
of the labioscrotal folds, and a single perineal opening
representing a urogenital sinus. The karyotype was
46,XY. Genitography showed a vaginal cavity of 2 cm
in length. Laparotomy revealed no uterus and gonads
located in the ovarian position in the pelvis. On the
right side, no vas deferens was seen, and the epididymis
was not attached to the gonad. On the left side, the
epididymis and vas deferens were found in a normal
position. Gonadal biopsy showed normal bilateral
testes (Fig. 1). Sonography did not show kidney
abnormalities. The cardiac malformation consisted of a
cocartation of the aorta and a patent ductus arteriosus.

**Figure 1** Gonadal histology of the patient’s testes at the age of 11
(hematoxylin and eosin × 10 magnification) showing eutrophic
testes with seminiferous tubules of normal size, increased number
of Sertoli cells (arrow) and Leydig cell hyperplasia (arrowhead).

**Table 1** Hormonal data of the patient at birth and at 11 years.

<table>
<thead>
<tr>
<th></th>
<th>At birth</th>
<th>Normal values (males)</th>
<th>At 11 years</th>
<th>Normal values (males)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone (ng/ml)</td>
<td>Basal</td>
<td>0.4</td>
<td>(0.01±0.56)</td>
<td>2.22</td>
</tr>
<tr>
<td></td>
<td>After HCG stimulation</td>
<td>4.92</td>
<td>(7.26±2.43)</td>
<td>n.d.</td>
</tr>
<tr>
<td>DHT (ng/ml)</td>
<td>LH (U/l)</td>
<td>n.d.</td>
<td>0.17</td>
<td>(0.089±0.043)</td>
</tr>
<tr>
<td></td>
<td>Basal</td>
<td>5</td>
<td>(6±3.7)</td>
<td>5.2</td>
</tr>
<tr>
<td></td>
<td>After stimulation</td>
<td>n.d.</td>
<td>44</td>
<td>(16.2±12.5)</td>
</tr>
<tr>
<td>FSH (U/l)</td>
<td>Basal</td>
<td>4.5</td>
<td>(1.5±0.8)</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>After LHRH stimulation</td>
<td>n.d.</td>
<td>18</td>
<td>(8.6±5.4)</td>
</tr>
<tr>
<td>AMH (ng/ml)</td>
<td>n.d.</td>
<td>4.3</td>
<td>(15–29.6)</td>
<td></td>
</tr>
</tbody>
</table>

DHT, dihydrotestosterone; LH, luteinizing-hormone; FSH, follicle-stimulating hormone; LHRH, LH releasing hormone; AMH, anti-
müllerian hormone.
Sex assignment

Female sex assignment was chosen according to the clinical phenotype and the partial androgen resistance. At 1 year of age, a feminizing genitoplasty with opening of the urogenital sinus and burying of the penoscrotal structure was performed. The gonads were not removed.

Follow-up during childhood

The patient is now a 20-year-old woman. The coarctation of the aorta and the patent ductus arteriosus were operated on at the age of 8. At 10 years of age, growth of pubic hair without breast development occurred. Hormonal evaluation at the age of 11 revealed a testosterone level of 2.22 ng/ml. Dihydrotestosterone (DHT) level was 0.17 ng/ml with a normal T/DHT ratio of 13. LH and FSH level were as follows: a slightly elevated LH of 15.2 and a slightly elevated FSH of 18 U/l. Antimüllerian hormone (AMH) of 4.3 ng/ml was below the normal range for Tanner stage II (Table 1). No growth of the clitoris under the influence of elevated androgen levels at the beginning of puberty was observed. Subsequently, gonadectomy was performed. Both gonads were of normal size for age. Histology revealed ‘Sertoli-rich’ seminiferous tubules with raficarization of spermatogonia and Leydig cell hyperplasia (Fig. 1). There were no signs of gonadoblastoma. Until now, follow-up of renal function has not revealed proteinuria.

Molecular analysis

Methods

Genomic DNA was extracted from peripheral blood leukocytes with the Qiamp DNA blood kit (Qiagen, Courtaboeuf, France). Exons 1-8 of the androgen receptor gene and exons 1-5 of the 5α-reductase type 2 gene were amplified using the following primers:

- Ex1F 5'-CAGCGCTGACGTCTCCA-3', Ex1R 5'-GGTG- GTCTCA五GAGGGAGAG-3', Ex2F 5'-GTTGCTGTGTCAG- ACCAC-3', Ex2R 5'-AATCCGTGGGAGAGGAG-3', Ex3F 5'-TCTCGTGTCCTCCCCAAC-3', Ex3R 5'-GGTG-CCCAAGGACCAGAC-3', Ex4F 5'-TCTATTGCTTTTGAAGAAAGAG-3', Ex4R 5'-CTTTGAAAATGTCTAACAG-3', Ex5F 5'-CTCTGGGATCTGGG-3', Ex5R 5'-GCCGACTGCAAGGCTAC-3', Ex6F 5'-ATTTCCAAATGGCGACTTG-3', Ex6R 5'-AAAGGGGCCTAAGTATGAA-3', Ex7F 5'-CTCCAGTGCTCCTCCCTCCT-3', Ex7R 5'-CTCTTTGAACTCCTTGCC-3', Ex8F 5'-CTACTAGTGGAGTTGCTTT-3', Ex8R 5'-TCAT-GAATAACCCAACC-CTAGCC-3', Ex9F 5'-GAAGTCAAGCTTTGGGCC-3', Ex9R 5'-CTCATCACAAATTTCCATTTCCCCA-3', Ex10F 5'-CTCTCAACTGCGGCGTTGAG-3', Ex10R 5'-TGAGGAGGAGATTCAG-3'.

PCRs were performed with the Taq PCR Master Mix Kit (Qiagen). PCR products were verified for correct length on agarose gel and purified, using Qiaquick PCR columns (Qiagen). Automatic sequencing of the PCR products was performed with the ABI Prism BigDye terminator sequencing kit and the ABI 310 genetic analyzer according to the manufacturer’s instructions (Applied Biosystems, Courtaboeuf, France).

Results

Molecular analysis of the androgen receptor was performed in early childhood, as the phenotype and the hormonal data pointed to partial androgen insensitivity syndrome. No sequence abnormality was found. As Wolffian ducts were present, in later childhood molecular analysis of the 5α-reductase type 2 gene was performed, and no sequence abnormalities were detected. Subsequently, after ruling out these most common genetic defects leading to disturbed sex differentiation, sequencing of the WT1 gene was performed. A heterozygous C to T mutation was found in exon 2, changing proline to serine at position 181 (Fig. 2). The same heterozygous mutation was detected in the genomic DNA of the healthy mother. The father did not carry the mutation (data not shown).

Discussion

The patient’s mutation (P181S) is the first germline WT1 missense mutation in the N-terminal coding region identified in an XY individual with genital malformation, normal androgen-producing testes and absence of kidney disease (Fig. 2). In addition, the patient presented an associated congenital heart defect. The patient inherited the mutation from the heterozygous XX mother, who has developed neither nephropathy nor Wilms' tumor at her present age of 49.

The same P181S mutation was previously described in two patients. The mutation was identified in the tumoral tissue of an XY patient with Wilms' tumor, but without genital malformation (14), and Schumacher et al. reported a germline P181S substitution in an XX female with Wilms' tumor (15).

In comparison to the vast majority of WT1 mutations in the C-terminal DNA-binding zinc finger region, very few N-terminal germline mutations have been reported. Through the WT1 mutation database (http://www.umd.necker.fr/2003/), it was suggested that N-terminal nonsense mutations, in contrast to C-terminal mutations, do not result in nephropathy but only in Wilms’ tumor (8) (Fig. 2).

C-terminal and N-terminal WT1 mutations act through different mechanisms. The C-terminal WT1 mutants exert a dominant negative effect, as in DDS, since they lose their DNA-binding and transactivation capacities but retain their self-association domain.
The patient’s mutation represented as the partial sequence of exon 2 of the WT1 gene, showing a heterozygous C to T mutation leading to a proline to serine substitution at position 181 (P181S). The different types and ‘hot spots’ of WT1 mutations in patients with early-onset, late-onset and absence of clinical nephropathy are indicated.

Figure 2 The patient’s mutation represented as the partial sequence of exon 2 of the WT1 gene, showing a heterozygous C to T mutation leading to a proline to serine substitution at position 181 (P181S). The different types and ‘hot spots’ of WT1 mutations in patients with early-onset, late-onset and absence of clinical nephropathy are indicated.
which is essential for dimerization (16). In Frasier syndrome, the imbalance of + KTS and − KTS caused by intron 9 splice-site mutations might alter the expression of downstream genes necessary for normal development and function of the kidneys and gonads (6).

The P181S mutation in the early N-terminal part of the protein is not likely to hamper the DNA-binding and RNA-processing properties. But it can be assumed that the P181S mutation alters the self-associating capacities of WT1, as the mutation is located in the self-associating domain. In vitro studies are warranted to address this question. However, these studies of WT1 are extremely difficult and not very reliable, since WT1 function can change from repression to activation and vice versa depending on cell lines, expression vectors and the promoter of target genes (2, 4).

The absence of Wilms’ tumor in our patient, in contrast to the other described patients with the P181S mutation, is probably due to the absence of a ‘second hit’ on the intact allele, which is necessary for tumor development (17). To our knowledge, only two patients with WT1 mutations, XY karyotype and normal androgen-secretion gonads during puberty have been described (10, 18). The two patients presented severe hypospadias and cryptorchidism at birth. They showed normal masculinization during puberty with normal androgen levels, but elevated FSH and LH. At birth, our patient also displayed severe hypospadias and micropenis. Leydig cell function was intact with normal testosterone levels before and after HCG stimulation. At 11 years of age, testes were of normal size with ‘Sertoli-rich’ seminiferous tubules, absence of spermatogonia and Leydig cell hyperplasia with normal testosterone production (Fig. 1). The low AMH level at this age is difficult to explain. It indicates disturbed Sertoli cell function, but our patient had no müllerian remnants. One might therefore suspect a progressive alteration in Sertoli cell function with age.

The apparent phenotype of undervirilization with normal testosterone production in the neonatal and pubertal periods led to the diagnosis of androgen resistance. Since the androgen receptor gene sequence was normal, one could hypothesize that WT1 has some regulatory impact on androgen receptor function or expression. The androgen receptor promoter contains multiple WT1 binding sites (19), and it has been shown in vitro that WT1 could regulate androgen receptor transcription (19). Unfortunately, no genital skin fibroblasts of the patient were available to study androgen receptor expression.

Genotype–phenotype analysis of the reported cases suggests that the type of WT1 mutation might influence the severity of the gonadal malformation, as it does in the development of nephropathy (Fig. 2). Missense and splice-site mutations, which lead to an alteration in the zinc finger-coding region and the subsequent DNA- and RNA-binding functions, most likely result in a more severe phenotype, ranging from gonadal dysgenesis to streak gonads with a high risk of gonadoblastoma. In patients with N-terminal mutations, gonadal histology might reveal a less severe clinical spectrum from normal testis to mild gonadal dysgenesis. Androgen secretion might remain mainly intact in later life (7, 8).

Regarding the heart defect presented by our patient, the mice knockout phenotype (20) and in vitro data suggest a role of WT1 in heart development (21–23). However, the XX mother and the reported XX female carrying the P181S mutation did not display a heart defect, and coarctation of the aorta and patent ductus arteriosus are frequent abnormalities. The patient’s heart defect is thus most likely a coincidental association.

The particular phenotype of our patient, with genital malformation, normal androgen-producing testes and absence of nephropathy in both patient and mother, gives further evidence that N-terminal nonsense and missense mutations do not lead to nephropathy. However, they can lead to genital malformation, suggesting that genital development is more sensitive to gene dosage than kidney development in humans (24).

Acknowledgement

This work was supported by the ESPE Research Fellowship sponsored by Novo Nordisk AIS (to BK).

References


www.eje.org


